LLY · Eli Lilly and CompanyPharma Other · Pharma Cardiometabolic · Pharma Oncology · Pharma Immunology · Pharma Neuroscience
Business Model
Eli Lilly discovers, manufactures, and sells branded prescription medicines, and its economics are now dominated by the incretin (GLP-1) franchise — the tirzepatide injectables plus the new oral orforglipron — sold into a fast-growing obesity and diabetes market it leads as half of a duopoly.
Lilly makes money by discovering, patenting, manufacturing, and selling branded prescription drugs. Revenue is volume times net realized price, and for a patent-protected originator the price is set by clinical value and payer negotiation, not open competition, until a drug loses exclusivity and generics collapse its price. The economic engine today is the incretin class sold into obesity and type-2 diabetes.
The premium layer is best-in-class efficacy plus breadth across routes of administration. Lilly holds a leading injectable, the first oral small-molecule GLP-1, and the highest-efficacy next-gen triple agonist all in-house, so it can serve the premium injectable tier and the mass-market oral tier from one pipeline. Deeper weight-loss efficacy and label expansion into sleep apnea, heart failure, and osteoarthritis widen both the reimbursable market and the formulary moat.
Lilly reports a single pharmaceutical segment, so the durable structure is read by franchise and geography rather than by reportable unit. Cardiometabolic — the incretins plus legacy diabetes — is the dominant share of revenue at about three-quarters, with oncology, immunology, and neuroscience the smaller, more diversified balance. Geographically the US is about two-thirds of revenue, so US pricing policy is the single largest swing factor.
The economics are classic branded-pharma: a very high gross margin (cost of goods is a small fraction of price) funds heavy R&D at about a fifth of revenue and, unusually, a >$50B manufacturing build. Small-molecule orforglipron is structurally cheaper and faster to scale than injectable peptides, which is what lets Lilly defend margin as it discounts into the mass market. Operating leverage is high because price, not unit cost, drives the P&L.
Investment Verdict
Lilly is the structural winner of the incretin super-cycle with the deepest next-gen obesity pipeline and a compounding manufacturing moat; at the September 15 anchor, the unchanged scenario set produces a 15.393756% probability-weighted return and a Buy action, though only narrowly above the threshold.
px · close · 2026-09-21
Orforglipron's launch exceeds expectations and adds a large naive/mass-market cohort; retatrutide TRIUMPH confirms 28-30% weight loss with an on-schedule Q1 2027 FDA filing, setting up a best-in-class 2027-28 launch; tirzepatide volume outruns price erosion with Mounjaro+Zepbound past a $60B annualized run-rate; and Medicare/TrumpRx expand covered lives faster than the price concession. CY2027E EPS toward $54 at a 30x multiple.
FY2026 lands within the raised $85-87B revenue / $35.50-36.50 reported non-GAAP EPS guide, with a normalized base near $39 after one-time acquired IPR&D; orforglipron ramps solidly but gradually as capacity and formulary access scale; low-to-mid-teens US price erosion persists but volume more than offsets it; US GLP-1 share holds about 60%. CY2027E EPS about $48 at 26x.
US net price erosion accelerates beyond low-to-mid-teens as MFN, Medicare, TrumpRx, and oral-pill competition compress GLP-1 pricing faster than volume offsets; competitive launches (Novo amycretin/oral Wegovy, Amgen MariTide, Roche CT-388) take meaningful share; orforglipron underwhelms or a tolerability signal emerges; and the multiple re-rates toward the pharma-biotech band. CY2027E EPS about $40 at 20x.
EntryAdd on a pullback that reopens the upside gap, or on a fresh datapoint that lifts CY2027E EPS visibility: retatrutide's FDA filing landing on schedule (Q4 2026/Q1 2027), orforglipron ramping ahead of plan, or a guidance raise at a quarterly print that pushes the base target back above the price.
ExitTrim if the thesis erodes at the franchise level: US net price erosion accelerating past about -15% as pricing policy and oral-pill competition outrun volume, a competitor printing >28% weight loss with a cleaner dosing/safety profile, or a retatrutide/orforglipron tolerability signal that blunts the pipeline.
Consensus FY27E EPS $47.32 sits closest to our Base EPS $48.00 — the market already prices the Base earnings as its base case.